19
Early Stage Deal Term Report A thorough analysis of private company investment Deal Terms 2: Analysis Breakdown Section 1 Report Overview 3: Valuations by Quarter 4: Regional Breakdown 4-14: Deal Term Teardown 15: Definition of Terms Section 2 Analysis 16-18: VC Experts Overview 19: Terms of Use Section 3 Appendix

Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Early Stage Deal Term ReportA thorough analysis of private company investment Deal Terms

• 2: Analysis Breakdown

Section 1 Report Overview

• 3: Valuations by Quarter

• 4: Regional Breakdown

• 4-14: Deal Term Teardown

• 15: Definition of Terms

Section 2 Analysis

• 16-18: VC Experts Overview

• 19: Terms of Use

Section 3 Appendix

Page 2: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

REPORT OVERVIEWThis represents a sampling of data in the VC Experts database

2

The “Company Intelligence Report” by VC Experts is aimed at providing specific deal terms and estimated post-money valuations for the venture-backed company. Included in the report are national industry averages and investment rounds with deal terms. VC Experts has compiled this intense level of data from Federal and State regulatory filings, as well as strategic partners, to aid in providing better transparency of private company information.

An

alys

is B

reak

do

wn

Total Number of Companies in Analysis 515

Available Deals 549

Industry/Sector All

Date Range Q4 2013 - Q4 2014

Region(s) All (US)

Rounds Included Seed, Series A, Series B

Round Direction All

Stock Type All

Liquidation Multiple All

Liquidation Preference All

Page 3: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

3

Early Stage Valuations

Complete Company Profile Reports can be purchased here at the VC Experts Report Center

$

$100

$200

$300

$400

$500

$600

$700

$800

$900

$1000

Mill

ion

s

Early Stage Valuations by Quarter

Seed Series A Series B

Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014

Mixpanel, Inc

YourPeople, Inc.

Vicarious FPC, IncThe Honest Company, Inc.

Indiegogo, Inc.

Beepi, Inc.

Page 4: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

4

Regional Breakdown

DC/Metroplex1%

Colorado1%

Northwest1%

Philadephia Metro

1%

Southeast2% Southwest

3%New York State

4%

Midwest4%

Southern California

9%

New England12%

Silicon Valley62%

Page 5: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Seed9%

Series A42%

Series B49%

Rounds(Q4 2013 - Q4 2014)

7%

46%

47% Q1 2014

8%

39%53% Q2 2014

15%

37%

48% Q3 2014

6%

43%51% Q4 2014

5

Rounds of Financing

• Series B Rounds led the way with 49% of financings analyzed

• Only 9% of Deals analyzed were defined as “Seed” Rounds, as stated in the filings

• Average Valuations increased dramatically between the Series A & Series B

$1

$4

$22

$ $5 $10 $15 $20 $25

Seed

Series A

Series B

Average Valuation by Round (In Millions)

6%

48%

46% Q4 2013

Page 6: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Down Round

7%

Flat Round8%

Not Applicable

28%

Up Round57%

Direction (Q4 2013 - Q4 2014)

6%8%

28%58%Q4 2013

7%6%

32%55%Q1 2014

7%10%

22%61%

Q2 2014

5%7%

35%53% Q3 2014

13%

3%

22%62%

Q4 2014

6

Round Direction

**Why are some results marked as N/A?If N/A was used as indication for the "Round Direction" and/or the "Liquidation Preference for the Current Round", then this was due to there not being a previous round of financing for that particular company. If N/A was used for the "Type of Preferred Stock", then the preferred stock was not a "Conventional Convertible" or a "Participating Preferred"

• Up rounds were found in 57% of the deals analyzed

• Following the Up rounds were those that did not have a prior round of financing. (Typically these would be Seed or Series A rounds of financing)

• Companies that had down rounds:

Handybook, Inc Plastiq, Inc Aushon BioSystems, Inc. DICOM Grid, Inc. Redshift Systems Corp

$2

$7

$11

$19

$ $5 $10 $15 $20

Not Applicable

Down Round

Flat Round

Up Round

Average Valuation (In Millions)

Page 7: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Conventional Convertible

72%

Participating Preferred

28%

Stock Type(Q4 2013 - Q4 2014)

7

Security Description

• 28% of the deals analyzed contained Participating Preferred stock

• 62% of those Participating Preferred deals were not capped

• Companies that fell into this group included:

Histogenics Corp Blend Therapeurics Inc Aushon BioSystem, Inc

Crashmob, Inc Eyelation, Inc

74%

26%

Q4 2013

74%

26%

Q1 2014

68%

32%

Q2 2014

76%

24%

Q3 2014

68%

32%

Q4 2014

$6

$15

$ $2 $4 $6 $8 $10 $12 $14 $16

Participating Preferred

Conventional Convertible

Average Valuation (In Millions)

Page 8: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

55%

45% Q4 2013 47%53% Q1 2014

61%

39%

Q2 2014

84%

16%

Q3 2014

67%

33%

Q4 2014

No62%

Yes38% Capped

Participation(Q4 2013 - Q4 2014)

8

Capped Participation

• 38% of the deals analyzed that were Participating Preferred included a Cap in participation

• Companies that fell into this category include:

Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works

$4

$11

$ $2 $4 $6 $8 $10 $12

No

Yes

Average Valuation (In Millions)

Page 9: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

>1 - 2x4%

>2 - 3x0%

0 - 1x96%

Liquidation Multiple

(Q4 2013 - Q4 2014)

3% 1%

96%

Q4 2013

2%

98%

Q1 2014

4% 1%

95%

Q2 2014

5%

95%

Q3 2014

11%

89%

Q4 2014

9

Liquidation Multiple

• A liquidation multiple of 1x was found in 96% of the deals analyzed. This is typical of a majority financings analyzed across industries

• Approximately 4% of the deals analyzed had a liquidation multiple greater than 1x

• Companies with > than 1x include:

LiquidM, Inc LotLinx, Inc Cloudcade, Inc Krave Pure Foods, Inc

$12

$24

$ $5 $10 $15 $20 $25

0 - 1x

>1 - 2x

Average Valuation (In Millions)

Page 10: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

3%4%

93%

Q4 2013

3%5%

92%

Q1 2014

4%4%

92%

Q2 2014

3%1%

96%

Q3 2014

6% 5%

89%

Q4 2014

N/A**4%

Full Ratchet

3%

Weighted Average

93%

Anti-Dilution(Q4 2013 - Q4 2014)

10

Anti-Dilution

• Historically, weighted average is the most common Anti-Dilution provision, and this sample was no different with 93% of the deals providing this provision

• Full Ratchet anti-dilution provisions occurred in 3% of the deals analyzed

• Deals that Full Ratchet Anti-Dilution occurred were as follows:

Histogenics Corp Cloudcade Inc CrowdBouncer, Inc

$1

$3

$13

$ $2 $4 $6 $8 $10 $12 $14

N/A

Full Ratchet

Weighted Average

Average Valuation (In Millions)

**Why are some results marked as N/A?If N/A was used as indication for the "Round Direction" and/or the "Liquidation Preference for the Current Round", then this was due to there not being a previous round of financing for that particular company. If N/A was used for the "Type of Preferred Stock", then the preferred stock was not a "Conventional Convertible" or a "Participating Preferred"

Page 11: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Junior0%

Not Applicable

29%

Pari Passu49%

Senior22%

Liquidation Preference

(Q4 2013 - Q4 2014)

1%

27%

54%

18%

Q4 2013

1%

32%

47%

20%

Q1 2014

23%

52%

25%

Q2 2014

35%

43%

22%

Q3 2014

22%

46%

32%

Q4 2014

11

Liquidation Preference

**Why are some results marked as N/A?If N/A was used as indication for the "Round Direction" and/or the "Liquidation Preference for the Current Round", then this was due to there not being a previous round of financing for that particular company. If N/A was used for the "Type of Preferred Stock", then the preferred stock was not a "Conventional Convertible" or a "Participating Preferred"

• A Senior Liquidation Preference was found in 22% of those deals analyzed

• Pari Passu Liquidation Preference was found in 49% of the deals analyzed

• 29% of the deals analyzed did not have a Liquidation Preference, meaning there was not another series of preferred stock in the liquidation stack (Typically these would be Seed or Series A rounds of financing.)

$3

$6

$21

$35

$ $5 $10 $15 $20 $25 $30 $35 $40

Not Applicable

Senior

Pari Passu

Junior

Average Valuation (In Millions)

Page 12: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

66%

11%

20%

3%

Q4 2013

65%

18%

15%2%

Q1 201455%

25%

18%2%

Q2 2014

63%14%

21%

2%

Q3 201454%

19%

27%

Q4 2014

8%61%

< 8%18%

Not Stated19%

>8% 2%

Dividend Rate(Q4 2013 - Q4 2014)

12

Dividend Rate

• Historically, an 8% Dividend Rate has been used in a majority of the deals analyzed, and this was true in 61% of the deals from this sample

• Also, 86% of the deals analyzed included Non-Cumulative dividends

• Examples of non-traditional Dividend Rates were as follows:

Paxata, Inc (9%)

5th Planet Games, Inc (13%)

YourPeople, Inc (5%)

Indiegogo, Inc (7%)

$5

$9

$9

$157

$ $50 $100 $150

>8%

Not Stated

8%

< 8%

Average Valuation (In Millions)

Page 13: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

85%

15%

Q4 2013

86%

14%

Q1 2014

81%

19%

Q2 2014

89%

11%

Q3 2014

95%

5%

Q4 2014

No86%

Yes14%

Cumulative Dividend

(Q4 2013 - Q4 2014)

13

Cumulative Dividend

• Non-Cumulative Dividend were found in 86% of the deals analyzed

• Examples of companies that contained a Cumulative Dividend deal term were as follows:

ezCater, Inc Dailybreak, Inc Convergent Dental, Inc The Honest Company, Inc Qliance Medical Mgmt, Inc

$12

$16

$ $5 $10 $15 $20

No

Yes

Average Valuation (In Millions)

Page 14: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

92%

8%

Q4 2013

95%

5%

Q1 2014

92%

8%

Q2 2014

94%

6%

Q3 2014

92%

8%

Q4 2014

No93%

Yes7%

Pay to Play(Q4 2013 - Q4 2014)

14

Pay to Play

• 7% of the deals did have a Pay-to-Play penalty, with the most frequent being the “conversion to common stock”, followed closely by “the conversion to common stock and loss of anti-dilution”

• Companies that had deal terms with Pay to Play penalties were as follows:

Kala Pharmaceuticals, Inc Visterra, Inc Mitokyne, Inc Redshift Systems Corp Crashmob, Inc

$9

$13

$ $2 $4 $6 $8 $10 $12 $14

Yes

No

Average Valuation (In Millions)

Page 15: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

82%

18%

Q1 2014

74%

26%

Q2 2014

80%

20%

Q3 2014

81%

19%

Q4 2014

No76%

Yes24%

Redemption(Q4 2013 - Q4 2014)

15

Redemption

• 76% of the deals analyzed did not include Redemption rights

• Companies that did include Redemption Rights in the Term Sheet were as follows:

Handybook, Inc Gridco, Inc Silvergate Pharma, Inc DraftKings, Inc Pronutria, Inc

$12

$14

$ $2 $4 $6 $8 $10 $12 $14 $16

No

Yes

Average Valuation (In Millions)

100%

Q4 2013

Page 16: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Preferred Stock - A class of capital stock that may pay dividends at a specified rate and that has priority over common stock in the payment of dividends and the liquidation of assets. Many venture capital investments use preferred stock as their investment vehicle. This preferred stock is convertible into common stock at the time of an IPO.

Round of Financing – The Series of Preferred or Common that is being authorized and issued in the current round.

Round Direction – Direction of the series preferred being issued based off of the current series issue price VS. the prior series issue price:

UP = current round is priced HIGHER than the prior round

FLAT = current round is priced the SAME as the prior round

DOWN = current round is priced LOWER than the prior round

Liquidation Preference – the order at which the assets or funds are dispersed upon a liquidation, dissolution, or winding up of a corporation, either voluntary or involuntary

Senior- the Series of Preferred being issued is SENIOR in liquidation preference to all other Preferred Stock and Common Stock

Pari Passu- the Series of Preferred being issued shares equally with one or more other Series of Preferred Stock but prior to the Common Stock

Junior – the Series of Preferred being issued is JUNIOR to one or Series of Preferred

N/A- Not Applicable is used if there is not a previous round of Preferred issued (EX: Series A round)

Multiple of the Liquidation Preference – The amount per share that a holder of a given series of Preferred Stock will receive prior to distribution of amounts to holders of other series of Preferred Stock or Common Stock based on the amount invested. This is usually designated as a multiple of the Issue Price, for example 2X or 3X.

Type of Preferred Stock –

Participating Preferred Stock - A Preferred stock in which the holder is entitled to receive the appropriate liquidation preference and after all payments have been made to the various Series of Preferred, the Participating Preferred Stock can participate in receiving any remaining funds or assets, on an “as if” converted basis, alongside the Common Stock shareholders.

Conventional Convertible Preferred – non-Participating, can convert to common and receive Pro Rata distribution, but CANNOT participate with the common on an “as if” converted basis.

Liquidation Cap – The Cap or Max Participation amount that the Participating Preferred Stock can received when participating

Anti-Dilution– Contractual measures that allow investors to keep a constant share of a firm's equity in light of subsequent equity issues. These may give investors preemptive rights to purchase new stock at the offering price.

Weighted Average –The investor's conversion price is reduced, and thus the number of common shares received on conversion increased, in the case of a down round; it takes into account both: (a) the reduced price and, (b) how many shares (or rights) are issued in the dilutive financing. See Broad-Based Ratchet and Narrow-Based Ratchet definitions.

Full Ratchet – The sale of a single share at a price less than the favored investors paid reduces the conversion price of the favored investors' convertible preferred stock "to the penny". For example, from $1.00 to 50 cents, regardless of the number of lower priced shares sold.

Redemption – The right or obligation of a company to repurchase its own shares.

Pay to Play Penalties – A requirement for an existing investor to participate in a subsequent investment round, especially a Down Round. Where Pay to Play provisions exist, an investor's failure to purchase its pro-rata portion of a subsequent investment round might result in one or more of:

Conversion to Common

Conversion to Shadow Preferred

Loss of Anti-Dilution protection

Loss of right to participate in future rounds

Cumulative Dividends – Dividends that accrue at a fixed rate until paid are "Cumulative Dividends" which are payments to shareholders made with respect to an investor's Preferred Stock. Generally, holders of Preferred Shares are contractually entitled to receive dividends prior to holders of Common Stock. Dividends can accumulate at a fixed rate (for example 8%) or simply be payable as and when determined by a company's Board of Directors in such amount as determined by the board. Because venture backed companies typically need to conserve cash, the use of Cumulative Dividends is customary with the result that the Liquidation Preference increases by an amount equal to the Cumulative Dividends.

16

Definition of Terms

Page 17: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Our Reputation hinges on our ability to provide accurate, verified data & content on the Private Market Financing Industry. We do this through a team of experienced specialists

adept at uncovering and analyzing even the most unusual financing structures.This approach allows us to deliver accurate data that empowers a level of transparency

that is unmatched and highly sought after.

Contact Us:(646) [email protected]

Page 18: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Private Company Filings

• Analyze term sheets

• Access to over 80,000 filings

• Download to .pdf

• Legal entity involved

Aggregate Level Reports

• Valuation Trends

• Industry specific Reports

• Deal Term trends and Analysis

• Custom requests available

Track Key Management

• See who is involved in each deal

• Over 40,000 people available

• Founders, Execs & Directors

• Research associated involvement

Granular Company Data

• Common & Preferred Prices

• Keep track of Valuations by round, industry & more

• Explore each round and detailsbehind the financing

More than just Data

• Understand Terminology: Searchable Glossary of Venture Capital terminology

• Master Financing Stages: Over 100 downloadable Legal Forms available

• Stay Informed: Weekly Blog Articles from Joe Bartlett and over 85 other contributors across the country

• Expand your knowledge: Access to The Encyclopedia of Venture Capital & Private Equity (7,000 pages of both fresh & evergreen material)

Page 19: Early Stage Deal Term Report - WordPress.com · Avalanche Biotech, Inc Sebacia, Inc Lumena Pharmaceuticals SAGE Therapeutics Sonoma Beverage Works $4 $11 $ $2 $4 $6 $8 $10 $12 No

Acceptance of AgreementThe provisions in this section are referred to as the "Terms of Use" and constitute an agreement between you and VCExperts.com. You acknowledge and agree that you have read the terms of use carefully, understand each of them and agree to be bound be all of them. If you do not agree to the Terms of Use, you may not access or otherwise use VCExperts.com and should exit the site. ModificationsVC Experts may modify the terms of this Agreement or any of the policies or guidelines governing the site, at any time and in its sole discretion, by posting the modified Terms of Use Agreement on the site. The modifications shall be effective upon such posting. You agree to review this Agreement periodically so that you are aware of any modifications. Your continued use of the site indicates your full acceptance of the Terms of Use Agreement in its then current form each time you use the site.Acknowledgment of Copyright and IndemnityVC Experts takes the matter of copyright violation very seriously. We make all possible efforts to ensure all articles are properly cited. Many articles are peer reviewed and authors or copyright holders sign agreements granting VC Experts a sub-license or a license to publish the content either online or in any media, depending on the agreement. Users are expected to follow proper citation and copyright laws if the are using VC Experts content as a primary or secondary source in any publication or written document. Content providers, paid subscribers and the free users of VC Experts specifically agree to indemnify VC Experts, Inc. against any copyright or intellectual property infringement case that may arise through the use of any content within the VC Experts' website.Assignment of Subscription or Contract. User agrees that their subscription to any VC Experts product or service may be assigned in part or in its entirety to any purchaser of all or substantially all of VC Experts business (or any asset or service pertaining to the line of business to which the Terms of Service relates).SecurityThis web site takes every precaution to protect our users' information. When you submit sensitive information via the web site, your information is protected both online and off-line.When our registration form asks you to enter sensitive information (e.g., credit card number, social security number), that information is encrypted and is protected with the best encryption software in the industry - Secure Socket Layer (SSL) protocol. While on a secure page, the lock icon at the bottom of the Microsoft Internet Explorer browser should be locked and the key icon on Netscape Navigator should be unbroken.Notice of New Services and ChargesOccasionally, we may also use the information we collect to notify you about important changes to our web site, new services and special offers we think you will find valuable. As our client, you will be given the opportunity to notify us of your desire not to receive these offers by clicking on a response box when you receive such an offer or by sending us an e-mail at [email protected] Compelled Disclosure of InformationWe may disclose information when legally compelled to do so, in other words, when we, in good faith, believe that the law requires it or for the protection of our legal rights.Links to Other Web SitesVC Experts reviews all links to third party websites and takes very seriously the review of the third-party material. Please remember that when you use a link to go from our web site to another web site, that that website has its own website policies. Your browsing and interaction on any other web site, including web sites which have a link on our web site, is subject to that web site's own rules and policies. Please read over those rules and policies before proceeding.ScriptsVC Experts does not allow scripts or automated computer programs of any kind. The use of any computer language script, automated or algorithmic program is expressly prohibited and a violation of terms of service and the copyright protections afforded to VC Experts.Limitation of LiabilityWe are not a law firm or a substitute for an attorney or law firm. We cannot provide any kind of advice, explanation, opinion, or recommendation about possible legal rights, remedies, defenses, options, selection of forms or strategies.The products offered by VCExperts.com are not a substitute for the advice of an attorney.The materials available on the site is provided "as is" without any express or implied warranty of any kind including warranties of merchantability, noninfringement of intellectual property, or fitness for any particular purpose. In no event shall vcexperts.com or its agents or officers be liable for any damages whatsoever (including, without limitation, damages for loss of profits, business interruption, loss of information) arising out of the use of or inability to use the materials, even if vcexperts.com has been advised of the possibility of such damages.Each user of this system assumes all responsibility and risk for the use of the materials. VCExperts.com does not assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any material on the sites. VCExperts.com will not be liable for any compensatory, special, direct, incidental, indirect, consequential damages, exemplary damages or any other damages resulting from loss of use, data, or profits, arising out of or in connection with the use or performance of the materials, however caused, whether for breach of contract, warranty, negligence, or otherwise, and whether of not VCExperts.com has been advised of the possibility of such damage.If this limitation of liability or the exclusion of warranty is held inapplicable or unenforceable for any reason, then VCExperts.com’s maximum liability for any type of damages shall be limited to U.S. $100.00. These limitations will apply notwithstanding the failure of any essential purpose of any limited remedy.IndemnificationYou agree to indemnify, defend and hold VC Experts and its affiliates, and any of their officers, directors, owners, agents, employees, information providers, licensors and licensees (collectively, the "Indemnified Parties") harmless from and against any and all liability and costs, including, without limitation, attorneys' fees and costs incurred by the Indemnified Parties in connection with any claim arising from your violation of this Agreement, state or federal securities laws or regulations, or any third party's rights, including but not limited to infringement of any copyright, violation of any proprietary right and invasion of any privacy rights.Use of InformationWe reserve the right, and you authorize us to the use and assignment of all information regarding your use of the site and all information provided by you in any manner consistent with our Privacy Policy.Governing LawThis Agreement shall be treated as though it were executed and performed in New York, New York, and shall be governed by and construed in accordance with the substantive law of the state of New York, without regard to conflict of laws provisions. Any cause of action by you with respect to VC Experts (and/or any information, products or services related thereto) must be instituted within one (1) year after the cause of action arose or be forever waived and barred. All legal proceedings arising out of or in connection with this Agreement shall be brought solely in New York, New York. You expressly submit to the exclusive jurisdiction of said courts and consent to extra-territorial service of process. Should any part of this Agreement be held invalid or unenforceable, that portion shall be construed consistent with applicable law and the remaining portions shall remain in full force and effect.Entire AgreementThis Agreement constitutes the entire and only agreement between us and you and supercedes any and all prior or contemporaneous agreements, representations, warranties and understandings with respect to the site, the content, goods and services provided by or through the site, and the subject matter of this Agreement. To the extent that anything in or associated with the site is in conflict or inconsistent with this Agreement, this Agreement shall take precedence. Our failure to enforce any provision of this Agreement shall not be deemed a waiver of such provision nor of the right to enforce such provision. Headings are for reference purposes only and in no way define, limit, construe or describe the scope or extent of this Agreement.

19

Terms of Use